Brand name: Bupredermal TM
Listen to the Pronunciation:
Active ingredients: buprenorphine
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured square patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured square patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured square patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured square patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured square patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured square patch with rounded corners on a aluminised rigid removable protective layer.The trade name and the strength are printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
What it is used for
BUPREDERMAL patches are indicated for the management of severe pain where: other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. BUPREDERMAL patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. BUPREDERMAL patches are not indicated as an as-needed (PRN) analgesia.
How to take it
The way to take this medicine is: Transdermal.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Beige coloured rectangular patch with rounded corners on an aluminised rigid removable protective layer. The trade name and the strength is printed on the patch.
Do I need a prescription?
This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient buprenorphine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems